Resistance to Molecularly Targeted Therapies in Melanoma
Malignant melanoma is the most aggressive type of skin cancer with invasive growth patterns. In 2021, 106,110 patients are projected to be diagnosed with melanoma, out of which 7180 are expected to die. Traditional methods like surgery, radiation therapy, and chemotherapy are not effective in the tr...
Main Authors: | Meet Patel, Adam Eckburg, Shahina Gantiwala, Zachary Hart, Joshua Dein, Katie Lam, Neelu Puri |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/5/1115 |
Similar Items
-
Treatment of Metastatic Melanoma with a Combination of Immunotherapies and Molecularly Targeted Therapies
by: Taylor Rager, et al.
Published: (2022-08-01) -
Novel Biomarkers and Druggable Targets in Advanced Melanoma
by: Pier Francesco Ferrucci, et al.
Published: (2021-12-01) -
Oligonucleotides and microRNAs Targeting Telomerase Subunits in Cancer Therapy
by: Adam Eckburg, et al.
Published: (2020-08-01) -
Genes Involved in Immune Reinduction May Constitute Biomarkers of Response for Metastatic Melanoma Patients Treated with Targeted Therapy
by: Miguel-Angel Berciano-Guerrero, et al.
Published: (2022-01-01) -
Melanogenesis and the Targeted Therapy of Melanoma
by: Cang Li, et al.
Published: (2022-12-01)